Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
AlzChem Group AG is a vertically integrated specialty chemicals company with roots dating back to 1908, renowned for its leadership in niche markets including Health & Pharma, Human & Animal Nutrition, Renewable Energies, Agriculture, Metallurgy, Fine Chemistry, Automotive & Defense, and Custom Manufacturing. The company specializes in high-quality, innovative products derived from the calcium carbide/calcium cyanamide chain, known as the NCN chain, utilizing basic inputs like lime, coal, and electricity to produce over 900 registered brands ranging from basic chemicals to complex specialties. Key offerings include the premium Creapure brand for high-purity creatine monohydrate in sports nutrition, the feed additive Creamino for animal growth, and Nitroguanidine for energetic applications in defense. Operating four production sites in Germany's East Bavarian chemical triangle (Trostberg, Schalchen, Hart, Waldkraiburg) and one in Sundsvall, Sweden, AlzChem employs around 1,725 people and generated 554.2 million EUR in sales in 2024. Its business is structured into Specialty Chemicals (59% revenue), Basics & Intermediates (36%), and Other & Holding, serving a diversified global customer base across Europe, North America, and Asia, addressing global challenges like climate change, nutrition, and security.
16.54% operating margin is respectable but not wide. ROIC at 23.91%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue growth slowed to 1.4%, essentially flat. This is a business that needs a catalyst.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
€566M
▲ +1.4% YoY
Net Income (TTM)
€67M
▲ +17.3% YoY
Op. Margin
17.27%
▲ +2.4pp YoY
ROIC
23.91%
▲ +0.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€125M
▲ +30.3% YoY
Op. Cash Flow (TTM)
€125M
▲ +30.3% YoY
Net Debt
-€32M
Net Cash Position
Cash & Equiv.
€76M
3Y CAGR: +1.2%
Continue Research